secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2026-10-05T21:06:37+00:00
Accession:  0001193125-26-414364
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Equillium wins Australian HREC and TGA clearance for Phase 1 EQ504 trial; dosing to start early November 2026
--------------------------------------------------------------------------------

- Equillium received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia under the Clinical Trial Notification scheme for a Phase 1 trial of EQ504.
- Company expects to begin dosing healthy participants by early November 2026.
- Phase 1 is a randomized, double-blinded, placebo-controlled, single-center study of once-daily oral EQ504 at doses from 0.1 mg to 3.0 mg.
- Part A: single ascending dose across 5 cohorts; Part B: multiple ascending dose across 3 cohorts with 10 days of once-daily dosing to assess steady-state PK, safety and tolerability.
- Part C: food-effect crossover cohort testing a high-fat meal's impact on bioavailability; longitudinal GI mucosal biopsies will assess CYP1A1 expression for target validation ahead of Phase 2.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312526414364/0001193125-26-414364-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312526414364/d174431d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-414364

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer